Relationship between salivary melatonin and severity of periodontal disease

Journal of Periodontology

Volumn 77, Issue 9, 2006, Pages 1533-1538

  Cutando, Antonio ^a   Galindo, Pablo ^a,c   Gómez Moreno, Gerardo ^a   Arana, Carlos ^a   Bolaños, Jorge ^a   Acuña Castroviejo, Darío ^a   Wang, Hom Lay ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c NONE   (Spain)

Author keywords

Melatonin; Periodontal diseases; Periodontal index; Plasma; Saliva

Indexed keywords

ANTIOXIDANT; FREE RADICAL; MELATONIN; SCAVENGER; SALIVA PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBACTERIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; FEMALE; GINGIVA; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATORY DISEASE; MALE; MULTIPLE REGRESSION; PERIODONTAL DISEASE; RADIOIMMUNOASSAY; SALIVA LEVEL; SCAVENGING SYSTEM; SCORING SYSTEM; SEX RATIO; STATISTICAL SIGNIFICANCE; VOLUMETRY; ADOLESCENT; BLOOD; CHEMISTRY; DISEASE COURSE; HOSPITALIZATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PERIODONTICS; PERIODONTITIS; PHYSIOLOGY; SALIVA;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; DISEASE PROGRESSION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MELATONIN; MIDDLE AGED; PERIODONTAL INDEX; PERIODONTITIS; SALIVA; SALIVARY PROTEINS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 33750143091     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2006.050287     Document Type: Article

References (33)

1. Reiter RJ. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-180.
2. Reiter RJ, Tan DX, Acuiia-Castroviejo D, Burkhardt S, Karbownik M. Melatonin: Mechanics and actions as an antioxidant. Curr Top Biophys 2001;24:171-183.
3. Marshall KA, Reiter RJ, Poeggeler B, Aruoma OI, Halliwell B. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med 1996;21: 307-315.
4. Reiter R, Tang L, García JJ, Muñoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 1997;60:2255-2271.
5. Reiter RJ. Cytoprotective properties of melatonin: Presumed association with oxidative damage and aging. Nutrition 1998;14:691-696.
6. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000;917:376-386.
7. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001;10: 467-476.
8. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocyte cell lines. J Pineal Res 2000;29:129-137.
9. Nakade O, Koyama H, Ariji H, Yajima A, Kaku T. Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 1999;27:106-110.
10. Koyama H, Nakade O, Takada Y, Kaku T, Lay KH. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 2002;17:1219-1229.
11. Laakso ML, Porkka-Heiskanen T, Alila A, Stenberg D, Johansson NG. Correlation between salivary and serum melatonin: Dependence on serum melatonin levels. J Pineal Res 1990;9:39-50.
12. McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Melatonin rhythm in human plasma and saliva. J Pineal Res 1987;4:177-183.
13. Mandel ID. Sialochemistry in diseases and clinical situations affecting salivary glands. Crit Rev Clin Lab Sci 1980;12:321-366.
14. Vakkuri O. Diurnal rhythm of melatonin in human saliva. Acta Physiol Scand 1985;124:409-412.
15. Cutando A, Gómez-Moreno G, Villalba J, Ferrera MJ, Escames G, Acuña-Castroviejo D. Relationship between salivary melatonin levels and periodontal status in diabetic patients. J Pineal Res 2003;35:239-244.
16. World Health Organization. Oral Health Surveys: Basic Methods, 4th ed. Geneva: World Health Organization; 1987:31-32.
17. Miles A, Thomas DR, Grey JE, Pugh AJ. Salivary melatonin assay in laboratory medicine longitudinal profiles of secretion in healthy men. Clin Chem 1987; 33:1957-1959.
18. Arendt J, Paunier L, Sizonenko PC. Melatonin radioimmunoassay. J Clin Endocrinol Metab 1975;40: 347-350.
19. Acuña-Castrovjejo D, Escames G, Carazo A, León J, Khaldy H, Reiter RJ. Melatonin mitochondrial homeostasis and mitochondrial-related diseases. Curr Top Med Chem 2002;2:133-151.
20. Reiter RJ. Aging and oxygen toxicity: Relation to changes in melatonin. Age (Omaha) 1997;20: 201-213.
21. Garcia-Maurino S, González-Haba MG, Calvo JR, Goberna R, Guerrero JM. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J Neuroimmunol 1998;92:76-84.
22. Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA, Mautalen C. Melatonin effects on bone: Experimental facts and clinical perspectives. J Pineal Res 2003; 34:81-87.
23. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
24. Liu D, Xu J, Figliomeni L, et al. Expression of RANKL and OPG mRNA in periodontal disease: Possible involvement in bone destruction. Int J Mol Med 2003; 11:17-21.
25. Theoleyre S, Wittrant Y, Kwan Tat S, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev 2004;15:457-475.
26. Masui T, Sakano S, Hasegawa Y, Warashina H, Ishiguro N. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials 2005;26: 1695-1702.
27. Takahashi N, Nobuyuki U, Takami M, Suda T. Cells of bone. Osteoclast generation. In: Bilezikian J, Raisz L, Rodan G, eds. Principles of Bone Biology, 2nd ed. San Diego: Academic Press; 2002:109-126.
28. Sandyk R, Anastasiadis P, Anninos P, Tsagas N. Is postmenopausal osteoporosis related to pineal gland functions? Int J Neurosci 1992;62:215-225.
29. Ostrowska Z, Kos-Kudla B, Swietochowska E, Marek B, Kajdaniuk D, Gorski J. Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis. Neuroendocrinol Lett 2001;22: 129-136.
30. Guerrero J, Pozo D, García-Mauriño S, Osuna C, Molinero P, Calvo J. Involvement of nuclear receptors in the enhanced IL-2 production by melatonin in Jurkat cells. Ann N Y Acad Sci 2000; 917:397-403.
31. Väänänen K, Zhao H. Osteoclast function. Biology and mechanism. In: Bilezikian J, Raisz L, Rodan G, eds. Principles of Bone Biology, 2nd ed. San Diego: Academic Press; 2002:127-141.
32. Roth J, Kim BG, Lin WL, Cho MI. Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999;274:22041-22047.
33. Battino M, Bullón P, Wilson M, Newman H. Oxidative injury and inflammatory periodontal diseases: The challenge of anti-oxidants to free radicals and reactive oxygen species. Crit Rev Oral Biol Med 1999;10: 458-476.